Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus low-dose nab-paclitaxel in previously treated advanced gastric and colorectal cancer
ChiCTR2300068977Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jul 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of toripalimab and paclitaxel in gastric cancer (GC), gastroesophageal junction adenocarcinoma and colorectal adenocarcinoma (2 cohorts), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Progression-free survival. Started Jul 2022; status: recruiting.
02
Drugs
toripalimabpaclitaxel
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinomacolorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2300068977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068977.